Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May 23:8:83.
doi: 10.3389/fpsyt.2017.00083. eCollection 2017.

Neurovascular Unit Dysfunction and Blood-Brain Barrier Hyperpermeability Contribute to Schizophrenia Neurobiology: A Theoretical Integration of Clinical and Experimental Evidence

Affiliations
Review

Neurovascular Unit Dysfunction and Blood-Brain Barrier Hyperpermeability Contribute to Schizophrenia Neurobiology: A Theoretical Integration of Clinical and Experimental Evidence

Souhel Najjar et al. Front Psychiatry. .

Abstract

Schizophrenia is a psychotic disorder characterized by delusions, hallucinations, negative symptoms, as well as behavioral and cognitive dysfunction. It is a pathoetiologically heterogeneous disorder involving complex interrelated mechanisms that include oxidative stress and neuroinflammation. Neurovascular endothelial dysfunction and blood-brain barrier (BBB) hyperpermeability are established mechanisms in neurological disorders with comorbid psychiatric symptoms such as epilepsy, traumatic brain injury, and Alzheimer's disease. Schizophrenia is frequently comorbid with medical conditions associated with peripheral vascular endothelial dysfunction, such as metabolic syndrome, cardiovascular disease, and diabetes mellitus. However, the existence and etiological relevance of neurovascular endothelial dysfunction and BBB hyperpermeability in schizophrenia are still not well recognized. Here, we review the growing clinical and experimental evidence, indicating that neurovascular endotheliopathy and BBB hyperpermeability occur in schizophrenia patients. We present a theoretical integration of human and animal data linking oxidative stress and neuroinflammation to neurovascular endotheliopathy and BBB breakdown in schizophrenia. These abnormalities may contribute to the cognitive and behavioral symptoms of schizophrenia via several mechanisms involving reduced cerebral perfusion and impaired homeostatic processes of cerebral microenvironment. Furthermore, BBB disruption can facilitate interactions between brain innate and peripheral adaptive immunity, thereby perpetuating harmful neuroimmune signals and toxic neuroinflammatory responses, which can also contribute to the symptoms of schizophrenia. Taken together, these findings support the "mild encephalitis" hypothesis of schizophrenia. If neurovascular abnormalities prove to be etiologically relevant to the neurobiology of schizophrenia, then targeting these abnormalities may represent a promising therapeutic strategy.

Keywords: blood–brain barrier; endothelial cell; endothelial nitric oxide synthase; neuroinflammation; neurovascular unit; nitric oxide synthase; oxidative stress; schizophrenia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Theoretical integration of human and experimental data linking neuroinflammation, oxidative stress, and genetic factors to neurovascular unit dysfunction and blood–brain barrier hyperpermeability in schizophrenia. Adapted with permission from Abbott et al. (16, 21). This figure describes several putative mechanisms linking neuroinflammation, oxidative stress, and eNOS uncoupling to neurovascular dysfunction and blood–brain barrier hyperpermeability in schizophrenia. ACE, angiotensin I-converting enzyme; AQP4, aquaporin 4; BH2, dihydrobiopterin; BH4, tetrahydrobiopterin; eNOS, endothelial nitric oxide synthase; MMP, matrix metalloproteinase; NAD(P)H, nicotinamide adenosine dinucleotide phosphate; NO, nitric oxide, ONOO, peroxynitrite; O2, superoxide; ROS, reactive oxygen species; VEGF, vascular endothelial growth factor.

Similar articles

Cited by

References

    1. Najjar S, Pearlman MD, Alper K, Najjar A, Devinsky O. Neuroinflammation and psychiatric illness. J Neuroinflammation (2013) 10:43.10.1186/1742-2094-10-43 - DOI - PMC - PubMed
    1. Anderson G, Berk M, Dodd S, Bechter K, Altamura AC, Dell’osso B, et al. Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2013) 42:1–42.10.1016/j.pnpbp.2012.07.016 - DOI - PubMed
    1. Najjar S, Pearlman DM. Neuroinflammation and white matter pathology in schizophrenia: systematic review. Schizophr Res (2015) 161(1):102–12.10.1016/j.schres.2014.04.041 - DOI - PubMed
    1. Takano A, Arakawa R, Ito H, Tateno A, Takahashi H, Matsumoto R, et al. Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106. Int J Neuropsychopharmacol (2010) 13:943–50.10.1017/S1461145710000313 - DOI - PubMed
    1. Kenk M, Selvanathan T, Rao N, Suridjan I, Rusjan P, Remington G, et al. Imaging neuroinflammation in gray and white matter in schizophrenia: an in-vivo PET study with [18F]-FEPPA. Schizophr Bull (2015) 41(1):85–93.10.1093/schbul/sbu157 - DOI - PMC - PubMed

LinkOut - more resources